AstraZeneca Just Spent $2.1 Billion to Pick a Fight With Merck

The drug is currently in phase 3 trials in China as a nebulized formulation, with a dry powder inhaler version in phase 2. AstraZeneca picked up exclusive rights outside of China to develop, manufacture, and commercialize TQC3721. Sino keeps the Chinese market.

Follow the Money

The deal structure tells you a lot about how AstraZeneca is thinking about risk.

Sino Biopharmaceutical gets $200 million upfront, with up to $1.9 billion in milestone payments tied to regulatory and commercial success. On top of that, Sino will collect tiered double-digit royalties on future sales outside China. AstraZeneca also secured exclusive global rights to certain future programs from the collaboration, essentially buying optionality beyond just this one molecule.

That $200 million upfront is relatively modest for a deal of this headline size. Most of the money only flows if TQC3721 actually works in global trials and reaches pharmacy shelves. It's the pharma equivalent of paying a small deposit on a house, with the rest contingent on the inspection going well.

Why AstraZeneca (and Why Now)

AstraZeneca isn't some newcomer wandering into the respiratory aisle for the first time. The company already sells Symbicort and Breztri, two major COPD inhalers that together generate roughly $1 billion per quarter in respiratory revenue. It has a 50-year history in lung disease, a global salesforce that knows every pulmonologist's coffee order, and deep clinical development expertise in inhaled therapies.

Adding a PDE3/PDE4 inhibitor to that portfolio is like a restaurant with a great wine list finally adding craft cocktails. It fills a gap and gives doctors a reason to keep prescribing within AstraZeneca's ecosystem rather than reaching for a Merck product.

The timing matters, too. AstraZeneca is simultaneously advancing tozorakimab, an anti-IL-33 antibody that hit its primary endpoints in two phase 3 COPD trials. The company has guided peak annual sales potential of $3 to $5 billion for that drug. Between tozorakimab and TQC3721, AstraZeneca is building a COPD portfolio that attacks the disease from multiple angles: biologics for the underlying inflammation, plus an inhaled PDE3/PDE4 drug for day-to-day airway management.

The Bigger Picture: A Two-Horse Race

Analysts are already framing this as a Merck vs. AstraZeneca showdown in the PDE3/PDE4 inhaled space. Ohtuvayre has the advantage of being first to market with real-world prescribing data (more than 5,300 doctors prescribed it by Q1 2025, with refills accounting for about 60% of dispensed prescriptions). That kind of early adoption is hard to replicate.

But AstraZeneca has advantages Merck doesn't. Its existing COPD portfolio means it can bundle TQC3721 into payer negotiations and physician relationships that are already built. It can offer both a nebulized version (for sicker patients or hospital settings) and a dry powder inhaler (for everyday use), giving it flexibility Ohtuvayre currently lacks.

Industry observers are also noting something broader: this deal is one of the clearest signals yet that China-originated respiratory assets now command multinational-scale economics. A $200 million upfront payment and $2.1 billion total value for a drug developed by a Chinese subsidiary would have been unthinkable five years ago. That ceiling is gone.

What to Watch

The next big milestones are straightforward. AstraZeneca needs to design and run global phase 3 trials for TQC3721 outside China, which will take years and cost hundreds of millions. If TQC3721 replicates its early lung function results in larger, more diverse populations, Merck will have a genuine competitor breathing down its neck.

For now, Merck still owns the only approved PDE3/PDE4 inhibitor in the world, and Ohtuvayre's commercial momentum is undeniable, with a trajectory pointing toward billions.

But monopolies in pharma rarely last. AstraZeneca just made sure this one won't, either.

BMS Is Printing Money Right Now. The Clock Is Ticking.

Bristol Myers Squibb just crushed Q2 estimates and hiked its 2026 forecast by billions, thanks to a blood thinner that won't quit and a new drug lineup firing on all cylinders. There's just one problem: the biggest patent cliff in pharma history is about 18 months away.